Cargando…

Pathogen inactivation treatment of triple‐dose apheresis platelets with amotosalen and ultraviolet a light

BACKGROUND: A triple storage (TS) set allows for pathogen inactivation (PI) treatment of triple‐dose apheresis platelet products with amotosalen + UVA. We evaluated the quality and metabolic parameters of platelet concentrates (PCs) pathogen inactivated and stored for 7 days. MATERIALS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Infanti, Laura, Pehlic, Vildana, Mitrovic, Sandra, Holbro, Andreas, Andresen, Silke, Payrat, Jean‐Marc, Lin, Jin‐Sying, Buser, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2022
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087429/ https://www.ncbi.nlm.nih.gov/pubmed/36124649 http://dx.doi.org/10.1111/tme.12913

Ejemplares similares

Clinical impact of amotosalen‐ultraviolet A pathogen‐inactivated platelets stored for up to 7 days
por: Infanti, Laura, et al.
Publicado: (2019)

Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance
por: Stivala, Simona, et al.
Publicado: (2017)

Preparation and Storage of Cryoprecipitate Derived from Amotosalen and UVA-Treated Apheresis Plasma and Assessment of In Vitro Quality Parameters
por: Kovacic Krizanic, Katarina, et al.
Publicado: (2022)

Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light
por: Lanteri, Marion C., et al.
Publicado: (2020)

Efficient inactivation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in human apheresis platelet concentrates with amotosalen and ultraviolet A light
por: Hindawi, S.I., et al.
Publicado: (2022)

Evaluation of amotosalen and UVA pathogen‐reduced apheresis platelets after 7‐day storage
por: Cancelas, Jose A., et al.
Publicado: (2022)

Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen‐reduction technology
por: Girard, Yvette A., et al.
Publicado: (2020)

Assessment of dengue virus inactivation in random donor platelets using amotosalen and ultraviolet A illumination
por: Kumar, Ankit, et al.
Publicado: (2022)

Protein Concentrations in Stored Pooled Platelet Concentrates Treated with Pathogen Inactivation by Amotosalen Plus Ultraviolet a Illumination
por: Arnason, Niels Arni, et al.
Publicado: (2022)

Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies
por: Santa Maria, Felicia, et al.
Publicado: (2022)

Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in human plasma
por: Azhar, Esam I., et al.
Publicado: (2020)

Profils d’anticorps dans le plasma de convalescent COVID-19 traité pour traitement de réduction des agents pathogènes par Amotosalen/UVA
por: Corash, Laurence, et al.
Publicado: (2021)

Effects of amotosalen treatment on human platelet lysate bioactivity: A proof-of-concept study
por: Christensen, Christian, et al.
Publicado: (2020)

Evaluation of bacterial inactivation in random donor platelets and single-donor apheresis platelets by the INTERCEPT blood system
por: Makroo, Raj Nath, et al.
Publicado: (2018)

Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units
por: Bubinski, Michal, et al.
Publicado: (2021)

The Effects of Ultraviolet Light and Riboflavin on Inactivation of Viruses and the Quality of Platelet Concentrates at Laboratory Scale
por: Mirshafiee, Hamideh, et al.
Publicado: (2015)

Cold storage of platelets in additive solution: the impact of residual plasma in apheresis platelet concentrates
por: Marini, Irene, et al.
Publicado: (2019)

Safety and Feasibility of Immunoadsorption with Heparin Anticoagulation in Preparation of ABO-Incompatible Kidney Transplantation: A Retrospective Single-Center Study
por: Junker, Till, et al.
Publicado: (2023)

The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates
por: Nebie, Ouada, et al.
Publicado: (2019)

Thromboelastography as a tool for quality check of apheresis platelets
por: Verma, Anupam, et al.
Publicado: (2016)

G-CSF Infusion for Stem Cell Mobilization Transiently Increases Serum Cell-Free DNA and Protease Concentrations
por: Stoikou, Maria, et al.
Publicado: (2020)

THE ULTRAVIOLET LIGHT AND PHOTOSENSITIZED INACTIVATION OF TOBACCO MOSAIC VIRUS
por: Oster, Gerald, et al.
Publicado: (1950)

Triple apheresis platelet concentrate quality after pneumatic tube system, conveyor box, and courier transport: An observational study
por: Reichert, Lena, et al.
Publicado: (2022)

Generation of Platelet Microparticles after Cryopreservation of Apheresis Platelet Concentrates Contributes to Hemostatic Activity
por: Eker, İbrahim, et al.
Publicado: (2017)

Comparison of abo antibody levels in apheresis platelets suspended in platelet additive solution and plasma
por: KC, Gayathiri, et al.
Publicado: (2021)

Desialylation of platelet surface glycans enhances platelet adhesion to adsorbent polymers for lipoprotein apheresis
por: Lauková, Lucia, et al.
Publicado: (2020)

Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation
por: Drexler, Beatrice, et al.
Publicado: (2020)

Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study
por: Khanna, Nina, et al.
Publicado: (2020)

Ultraviolet-Based Pathogen Inactivation Systems: Untangling the Molecular Targets Activated in Platelets
por: Schubert, Peter, et al.
Publicado: (2018)

A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen–UVA photochemical treatment
por: Knutson, F, et al.
Publicado: (2015)

The argument(s) for lowering the US minimum required content of apheresis platelet components
por: Benjamin, Richard J., et al.
Publicado: (2018)

Inactivation of SARS‐CoV‐2 infectivity in platelet concentrates or plasma following treatment with ultraviolet C light or with methylene blue combined with visible light
por: Hobson‐Peters, Jody, et al.
Publicado: (2023)

Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light
por: Gracheva, A. V., et al.
Publicado: (2022)

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

Efficacy and Safety of Pathogen-Reduced Platelets Compared with Standard Apheresis Platelets: A Systematic Review of RCTs
por: Pati, Ilaria, et al.
Publicado: (2022)

The safety and performance of the Spectra Optia apheresis system platelet depletion protocol in patients with elevated platelet counts
por: Lopert, Pamela, et al.
Publicado: (2022)

Antibody profiles in COVID‐19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment
por: Bagri, Anil, et al.
Publicado: (2022)

Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology
por: Cognasse, Fabrice, et al.
Publicado: (2022)

Apheresis Platelet Rich-Plasma for Regenerative Medicine: An In Vitro Study on Osteogenic Potential
por: Pulcini, Stefano, et al.
Publicado: (2021)

Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion
por: Duchez, Anne-Claire, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2vile2mm0tc440uhcl556n20s3